Firefly Neuroscience, Inc.
AIFF
$3.20
-$0.01-0.31%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 178.95% | 43.48% | -97.78% | 140.00% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 178.95% | 43.48% | -97.78% | 140.00% | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 178.95% | 43.48% | -97.78% | 140.00% | -- |
| SG&A Expenses | 39.88% | 1,131.29% | 61.23% | 89.30% | 198.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 64.88% | 541.94% | 65.02% | 100.18% | 81.67% |
| Operating Income | -63.50% | -559.66% | -295.91% | -99.82% | -79.50% |
| Income Before Tax | -251.58% | -559.85% | -291.33% | -105.12% | -17.34% |
| Income Tax Expenses | 100.00% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -251.44% | -559.85% | -291.33% | -105.12% | -17.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -251.44% | -559.85% | -291.33% | -105.12% | -17.45% |
| EBIT | -63.50% | -559.66% | -295.91% | -99.82% | -79.50% |
| EBITDA | -63.61% | -562.63% | -299.68% | -- | -79.10% |
| EPS Basic | -48.73% | -242.78% | -175.00% | 25.50% | 18.19% |
| Normalized Basic EPS | -13.91% | -242.93% | -177.19% | 25.93% | 30.78% |
| EPS Diluted | -48.73% | -242.78% | -175.00% | 25.50% | 18.19% |
| Normalized Diluted EPS | -13.91% | -242.93% | -177.19% | 25.93% | 30.78% |
| Average Basic Shares Outstanding | 136.27% | 92.47% | 41.59% | 175.99% | 43.57% |
| Average Diluted Shares Outstanding | 136.27% | 92.47% | 41.59% | 175.99% | 43.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |